1Q FY3/2020 Supplementary Material

Copyright 2019 Nihon Chouzai Co., Ltd. All rights reserved.

1.Financial Highlights

•	2015/3	2016/3	2017/3	2018/3	2019/3
Net sales (Millions of yen)	181,844	219,239	223,468	241,274	245,687
YoY growth rate	10.0%	20.6%	1.9%	8.0%	1.8%
Operating profit (Millions of yen)	6,647	10,489	8,519	10,587	6,733
Operating margin	3.7%	4.8%	3.8%	4.4%	2.7%
Profit attributable to owners of parent (Millions of yen)	2,778	6,329	4,638	6,104	3,790
Return on sales	1.5%	2.9%	2.1%	2.5%	1.5%
Shareholder's equity (Millions of yen)	17,635	32,473	36,447	41,504	41,068
Equity ratio	13.6%	20.6%	20.4%	22.2%	23.0%

	2016/3 1Q	2017/3 1Q	2018/3 1Q	2019/3 1Q	2020/3 1Q
Net sales (Millions of yen)	48,895	54,476	58,346	59,305	64,316
YoY growth rate	13.4%	11.4%	7.1%	1.6%	8.5%
Operating profit (Millions of yen)	2,052	1,620	2,184	501	1,770
Operating margin	4.2%	3.0%	3.7%	0.8%	2.8%
Profit attributable to owners of parent (Millions of yen)	1,221	981	1,122	40	833
Return on sales	2.5%	1.8%	1.9%	0.1%	1.3%
Shareholder's equity (Millions of yen)	18,669	33,044	37,171	41,170	41,534
Equity ratio	13.4%	20.2%	20.0%	21.0%	22.5%

2.Dispensing Pharmacy Business

	2015/3	2016/3	2017/3	2018/3	2019/3
No.of pharmacies opened	29	27	42	36	32
Including M&A	1	5	21	13	6
No.of pharmacies at the end of each period	511	527	557	585	598
Net sales of dispenshing pharmacy business (Millions of yen)	157,999	190,874	189,327	205,192	208,622
Sales per Pharmacy (Millions of yen)	314	367	349	359	352
No.of prescription (thousands)	11,695	12,301	12,949	13,739	14,192
Unit prices of prescription (yen)	13,330	15,297	14,382	14,739	14,458
			,	,	

	2016/3 1Q	2017/3 1Q	2018/3 1Q	2019/3 1Q	2020/3 1Q
No.of pharmacies opened	6	11	8	8	7
Including M&A	0	1	5	0	2
No.of pharmacies at the end of each period	512	533	564	589	600
Net sales of dispenshing pharmacy business (Millions of yen)	42,322	45,912	49,387	50,449	54,814
Sales per Pharmacy(Millions of yen)	82	86	88	85	91
No.of prescription(thousands)	2,990	3,126	3,356	3,483	3,576
Unit prices of prescription (yen)	13,962	14,518	14,547	14,234	15,110

3.Consolidated Balance Sheet

					(Mi	llions of yen)
(As of the end of the period)	2015/3 1Q	2016/3 1Q	2017/3 1Q	2018/3 1Q	2019/3 1Q	2020/3 1Q
Assets						
Current assets						
Cash and deposits	29,087	19,971	32,297	25,402	34,510	31,921
Notes receivable-trade	1,236	246	73	135	357	78
Accounts receivable-trade	17,078	20,254	23,989	25,901	18,844	16,738
Electronically recorded monetary claims-operating	_	801	987	940	940	1,119
Merchandise and finished goods	16,121	18,000	19,743	23,625	25,925	26,719
Work in process	764	1,090	2,520	2,458	1,489	1,092
Raw materials and supplies	3,169	4,498	5,020	5,704	5,730	6,010
Other	3,269	4,015	3,927	4,517	2,948	3,068
Allowance for doubtful accounts	(9)	(11)	(8)	(9)	(5)	(6)
Total current assets	70,717	68,869	88,551	88,677	90,742	86,742
Non-current assets						
Property, plant and equipment						
Buildings and structures, net	13,972	20,795	22,018	22,645	34,671	31,932
Land	15,327	17,126	17,937	18,166	19,397	16,844
Construction in progress	8,666	2,108	2,917	12,008	5,599	319
Other, net	5,887	9,549	11,528	15,387	15,780	19,909
Total property, plant and equipment	43,852	49,580	54,402	68,208	75,449	69,005
Intangible assets						
Goodwill	9,101	8,501	8,441	15,800	15,069	14,317
Other	1,787	1,660	1,591	2,194	2,557	2,331
Total intangible assets	10,889	10,162	10,033	17,994	17,627	16,649
Investments and other assets						
Investment securities	941	1,223	907	1,014	18	17
Lease and guarantee deposits	7,020	7,039	7,008	7,060	7,436	7,372
Other	2,470	2,661	2,616	2,616	4,757	4,823
Total investments and other assets	10,432	10,924	10,531	10,691	12,211	12,213
Total non-current assets	65,175	70,666	74,967	96,894	105,287	97,868
Total assets	135,892	139,535	163,518	185,572	196,030	184,610

Note: The amounts for the previous fiscal years in this materials do not reflect the revisions of the accounting standards.

					(Mi	llions of yen)
(As of the end of the period	2015/3 1Q	2016/3 1Q	2017/3 1Q	2018/3 1Q	2019/3 1Q	2020/3 1Q
Liabilities						
Current liabilities						
Notes payable-trade	2,047	_	_	_	_	_
Accounts payable-trade	35,079	36,955	44,328	43,779	46,211	48,638
Electronically recorded obligations-operating	_	1,760	2,948	2,190	4,858	4,011
Short-term loans payable	9,650	4,800	3,200	1,400	_	_
Current portion of bonds	7,000	_	7,000	_	_	_
Current portion of long-term loans payable	3,993	5,288	5,938	13,221	22,430	11,844
Income taxes payable	720	1,342	886	1,424	923	1,338
Provision for bonuses	1,038	1,130	1,241	1,403	1,555	1,660
Provision for directors' bonuses	1	_	_	_	_	_
Provision for sales rebates	153	167	4	_	_	_
Other	5,762	7,354	9,116	9,495	11,024	10,344
Total current liabilities	65,446	58,799	74,663	72,915	87,003	77,836
Non-current liabilities						
Bonds payable	7,000	7,000	_	_	_	_
Long-term loans payable	43,099	49,317	50,479	70,670	61,743	59,288
Provision for directors' retirement benefits	868	908	877	973	1,017	1,076
Net defined benefit liability	575	957	1,205	1,341	1,551	1,738
Other	2,757	3,883	3,248	2,499	3,542	3,131
Total non-current liabilities	54,301	62,066	55,810	75,485	67,854	65,234
Total liabilities	119,748	120,866	130,474	148,400	154,858	143,070
Net assets						
Shareholders' equity						
Capital stock	3,953	3,953	3,953	3,953	3,953	3,953
Capital surplus	4,754	4,754	10,926	10,926	10,926	10,926
Retained earnings	9,632	12,844	18,252	22,234	26,457	30,274
Treasury shares	(2,154)	(3,062)	(44)	(46)	(47)	(3,498)
Total shareholders' equity	16,185	18,489	33,088	37,068	41,289	41,655
Accumulated other comprehensive income						
Valuation difference on available-for-sale securities	180	380	170	246	0	(0)
Remeasurements of defined benefit plans	(222)	(200)	(214)	(142)	(119)	(121)
Total accumulated other comprehensive income	(41)	179	(44)	103	(119)	(121)
Non-controlling interests	` <u> </u>	_	· _	_	O O	5
Total net assets	16,144	18,669	33,044	37,171	41,171	41,539
Total liabilities and not accets	425,000	400 505	400 540	405 570	400,000	400,000

163,518

185,572

196,030

Total liabilities and net assets 135,892 139,535

Note:The amounts for the previous fiscal years in this materials do not reflect the revisions of the accounting standards.

196,030

4. Consolidated Statement of Income

(Millions of yen) (For the Three-month Period) 2019/3 1Q 2020/3 1Q 2015/3 1Q 2016/3 1Q 2017/3 1Q 2018/3 1Q Net sales 43,133 48,895 54,476 58,346 59,305 64,316 Cost of sales 40,136 45,248 47,693 36,005 49,547 53,169 Gross profit 7,127 8,759 9,228 10,652 9,757 11,147 Selling, general and administrative expenses 6,248 6,706 7,607 8,468 9,256 9,377 Operating profit 878 2,052 1,620 2,184 501 1,770 Non-operating income Commission fee 29 33 34 37 14 10 Rent income 66 94 94 104 110 105 Compensation income 48 Insurance return 69 Other 60 48 46 55 53 39 Total non-operating income 176 246 197 203 157 178 Non-operating expenses Interest expenses 200 197 186 169 149 103 Commission fee 5 7 7 4 3 3 Rent expenses 68 75 79 86 93 Other 70 58 53 41 62 37 Total non-operating expenses 279 332 320 291 281 263 Ordinary profit 756 1,896 1,545 2,090 398 1,710 Extraordinary income Gain on sales of non-current assets 0 3 0 0 27 Gain on sales of investment securities 8 Total extraordinary income 0 3 0 8 27 Profit before income taxes 757 1,548 2,090 406 1,896 1,738 Income taxes-current 592 1,046 779 1,389 871 1,324 Income taxes-deferred (128)(371)(212)(422)(504)(420)Total income taxes 464 675 567 967 367 903 Profit note 834 293 1,221 981 1,122 39 Profit (loss) attributable to non-controlling interests note 0 (1)

293

1,221

981

1,122

40

833

Note: Accompanying the revision of Accounting Standards for Business Combinations, etc., the names of items presented have been changed.

The rivised standards have been applied from the fiscal year ended March 31,2016.

Profit attributable to owners of parent note

5.Business Segment Performance

					(Mi	illions of yen)
	2015/3 1Q	2016/3 1Q	2017/3 1Q	2018/3 1Q	2019/3 1Q	2020/3 1Q
Dispensing pharmacy business						
Net sales	37,546	42,322	45,912	49,387	50,449	54,814
Segment profit	1,190	2,015	1,475	2,511	1,404	1,843
Pharmaceutical manufacturing and sales business		-			-	
Net sales	6,506	7,702	9,387	9,407	9,754	10,881
Segment profit	330	589	744	318	59	798
Medical Professional Staffing and Placement Business						
Net sales	1,499	2,087	2,588	3,107	3,217	3,597
Segment profit	327	441	440	601	401	651

6.Company Plofile

Trade Name

Established	March 1980
Headquarters	37F GranTokyo North Tower,1-9-1,Marunouchi,Chiyoda-Ku,100-6737 Tokyo
Capital	3,953.02 million yen
Total Number of Issued Shares	16,024,000 shares
Fiscal Year-end	March
Stock Exchange for Listing	Tokyo Stock Exchange(TSE) First Section
Securities Code	3341
Our Business	Management of health insurance dispensing chain pharmacies,
	manufacture and sales of generic drugs,
	employment placement and dispatching service of medical professionals,
	information provision and consulting
Number of pharmacies(As of June 30,2019)	600

NIHON CHOUZAI Co.,Ltd.